| Drug General Information |
| Drug ID |
D0W1HM
|
| Former ID |
DIB020486
|
| Drug Name |
nafadotride
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C22H27N3O2
|
| InChI |
InChI=1S/C22H27N3O2/c1-3-4-11-25-12-7-8-17(25)15-24-22(26)20-13-16(14-23)18-9-5-6-10-19(18)21(20)27-2/h5-6,9-10,13,17H,3-4,7-8,11-12,15H2,1-2H3,(H,24,26)
|
| InChIKey |
IDZASIQMRGPBCQ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4546259, 7980060, 9949320, 14877084, 26719799, 36278386, 46387001, 49681626, 50070521, 50071159, 53746209, 56311648, 57309748, 57356263, 85209195, 85789022, 92308559, 103195448, 104024628, 112212992, 124659097, 124800019, 125666021, 128154304, 135305572, 135610838, 135650679, 135698262, 139676272, 144235422, 162022313, 162023065, 163145133, 163751395, 172080492, 178125929, 179296009, 179323700, 184538718, 202558049, 219812685, 226935689, 241182349, 249617290, 252126122, 252270535, 252360576
|
| Target and Pathway |
| Target(s) |
D(3) dopamine receptor |
Target Info |
Antagonist |
[2]
|
|---|
| D(2) dopamine receptor |
Target Info |
Antagonist |
[2]
|
| D(4) dopamine receptor |
Target Info |
Antagonist |
[3]
|
| 5-hydroxytryptamine 1A receptor |
Target Info |
Agonist |
[4]
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04015:Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04080:Neuroactive ligand-receptor interaction
|
|
Dopaminergic synapsehsa04024:cAMP signaling pathway
|
|
Serotonergic synapse
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathway
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic Neurons
|
|
GPCRs, OtherWP666:Hypothetical Network for Drug Addiction
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction
|
|
GPCRs, OtherWP722:Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 44). |
|---|
| REF 2 | Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995 Dec;275(3):1239-46. |
|---|
| REF 3 | Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52. |
|---|
| REF 4 | Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. |
|---|
